Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | CA2 | P00918 | 4/20 | 0.38 |
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GLS | O94925 | 2/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | KDM4A | O75164 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | STK17B | O94768 | 1/20 | 0.37 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7496435 | 0.88 | PDPK1 (0.47) | PDPK1L3MBTL1CA1CA2CA12 | |
| SCHEMBL30842145 | 0.85 | PDPK1 (0.45) | PDPK1L3MBTL1CA1CA2CA12 | |
| SCHEMBL25625436 | 0.83 | PDPK1 (0.44) | PDPK1L3MBTL1KDM4ELMNAGLS | |
| SCHEMBL7496329 | 0.83 | PDPK1 (0.44) | PDPK1L3MBTL1CA1CA2CA12 | |
| SCHEMBL19990403 | 0.82 | PDPK1 (0.47) | PDPK1L3MBTL1CA1CA2CA12 | |
| SCHEMBL3870395 | 0.81 | FPR3 (0.48) | PDPK1L3MBTL1KDM4ELMNAGLS | |
| SCHEMBL19274418 | 0.81 | PDPK1 (0.47) | PDPK1L3MBTL1CA1CA2CA12 | |
| SCHEMBL24823222 | 0.80 | PDPK1 (0.42) | PDPK1L3MBTL1CA1CA2CA12 | |
| SCHEMBL25251839 | 0.79 | SMN1; SMN2 (0.41) | PDPK1L3MBTL1GLS | |
| SCHEMBL8134093 | 0.79 | PDPK1 (0.45) | PDPK1L3MBTL1CA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220305011-A1 | FACTOR XIIA INHIBITORS | UNIVERSITY OF LEEDS (GB) | 2022-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220305011-A1 | FACTOR XIIA INHIBITORS | F11, F13B, F12 | PDPK1 4151/4885L3MBTL1 4529/4885CA1 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.